OKYO Pharma (OKYO) outlines 100-patient Urcosimod trial in neuropathic corneal pain

Rhea-AI Filing Summary

OKYO Pharma LTD has filed a Form 6-K to furnish a news announcement about the regulatory registration pathway and a planned 100-patient multi-center clinical trial of Urcosimod in neuropathic corneal pain. The company states that the announcement, dated September 22, 2025, is included as Exhibit 99.1 to the report. The furnished information is not deemed filed under the Securities Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2025

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 22, 2025, OKYO Pharma LTD (the “Company”) issued this 6K announcing, the Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date:  September 22, 2025	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated September 22, 2025

4

FAQ

What did OKYO (OKYO) disclose in this Form 6-K?

OKYO Pharma LTD furnished a news announcement describing the registration pathway with a 100-patient multi-center clinical trial of Urcosimod in neuropathic corneal pain as Exhibit 99.1.

What is the focus of OKYO Pharma LTD’s new clinical trial?

The Form 6-K states that the company is pursuing a registration pathway with a 100-patient multi-center clinical trial of Urcosimod in neuropathic corneal pain.

How many patients are planned in OKYO’s Urcosimod trial?

The filing mentions a 100-patient multi-center clinical trial of Urcosimod in neuropathic corneal pain.

Is the Urcosimod trial announcement considered filed information for liability purposes?

The report states that the information in Exhibit 99.1 is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Who signed the OKYO Pharma LTD Form 6-K dated September 22, 2025?

The Form 6-K was signed on behalf of OKYO Pharma LTD by Keeren Shah, Chief Financial Officer.

Where can investors find the detailed announcement about Urcosimod from OKYO?

The detailed announcement is included as Exhibit 99.1 to the Form 6-K, titled "News Announcement, dated September 22, 2025."